Healthcare / Medical DevicesUpdated 2026-05-10 22:07 UTC

BIO.B stock hub

Bio-Rad Laboratories, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BIO.Bis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

6.8B

NYSE

Market data

Live price

Current market quote for this ticker.

Current price

BIO.B

In the news

Latest news · BIO.B

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E25.7

P25 12.3P50 18.4P75 33.1

Trailing P/E40.4

P25 14.9P50 23.2P75 38.5

ROE2.5

P25 -105.6P50 -46.5P75 -3.1

ROIC3

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BIO.B market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

242

Groups with data

Currency

USD

Showing 242 of 242 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000012208
Company name	Bio-Rad Laboratories, Inc.
Country	United States
Country code	US
Cusip	090572108
Employees	7,450
Employees Change	-250%
Employees Change Percent	-3.25
Enterprise value	$6.6B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
Industry	Medical Devices
Isin	US0905721082
Last refreshed	2026-05-10
Market cap	$6.8B
Market cap category	Mid-Cap
Price	$256
Price currency	USD
Rev Per Employee	347,637.58x
Sector	Healthcare
Sic	3826
Symbol	BIO.B
Website	https://www.bio-rad.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.48%
EV Earnings	39.25x
EV Sales Forward	2.52x
EV/EBIT	23.95x
EV/EBITDA	14.9x
EV/FCF	18.55x
EV/Sales	2.56x
FCF yield	5.24%
Forward P/E	25.65x
P/B ratio	0.99x
P/E ratio	40.36x
P/S ratio	2.63x
PE Ratio10 Y	65.56x
PS Forward	2.59x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	10.68%
EBITDA Margin	17.17%
FCF margin	13.79%
Gross margin	52.01%
Gross Profit	$1.3B
Gross Profit Growth	-1.92%
Gross Profit Growth Q	1.11%
Gross Profit Growth3 Y	-4.12%
Gross Profit Growth5 Y	-2.4%
Net Income	$168.8M
Net Income Growth5 Y	-47.16%
Pretax Margin	8.58%
Profit Margin	6.52%
Profit Per Employee	$22,658
ROA	1.79
Roa5y	1.87
ROCE	3.12
ROE	2.5
Roe5y	-3.05
ROIC	3.01
Roic5y	3.87

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	6.05%
Cagr15y	4.93%
Cagr1y	9.02%
Cagr20y	6.64%
Cagr3y	-18.26%
Cagr5y	-16.56%
EPS Growth5 Y	-46
FCF Growth	0.48%
FCF Growth Q	-18.22%
FCF Growth3 Y	41.31%
FCF Growth5 Y	-7.56%
OCF Growth	-0.95%
OCF Growth Q	-16.78%
OCF Growth10 Y	13.08%
OCF Growth3 Y	28.24%
OCF Growth5 Y	-4%
Revenue Growth	1.92x
Revenue Growth Q	1.15x
Revenue Growth3 Y	-2.32x
Revenue Growth5 Y	-0.83x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.27
Assets	$9.8B
Cash	$1.6B
Current Assets	$2.9B
Current Liabilities	$917M
Debt	$1.4B
Debt EBITDA	$2.69
Debt Equity	$0.2
Debt FCF	$3.86
Equity	$6.9B
Interest Coverage	5.61
Liabilities	$2.9B
Long Term Assets	$6.8B
Long Term Liabilities	$2B
Net Cash	$186.5M
Net Cash By Market Cap	$2.74
Net Cash Growth	-35.89%
Net Debt EBITDA	$-0.42
Net Debt Equity	$-0.03
Net Debt FCF	$-0.52
Tangible Book Value	$6.1B
Tangible Book Value Per Share	$228
WACC	9.29

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.21
Inventory Turnover	1.59
Net Working Capital	$897.1M
Quick ratio	2.19
Working Capital	$2B
Working Capital Turnover	$1.14

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	3.69%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	79.96%
1Y total return	9.01%
200-day SMA	482.4
3Y total return	-45.39%
50-day SMA	297.5
50-day SMA vs 200-day SMA	50under200
5Y total return	-59.56%
All Time High	818.6
All Time High Change	-68.78%
All Time High Date	2021-09-10
All Time Low	0.89
All Time Low Change	28,647.89%
All Time Low Date	1982-08-20
ATR	13.44
Beta	1.16
Ch YTD	-17.75
High	255.5
High52	321.1
High52 Date	2025-10-21
High52ch	-20.42%
Low	255.5
Low52	247.1
Low52 Date	2025-07-23
Low52ch	3.44%
Ma50ch	-14.11%
Price vs 200-day SMA	-47.02%
RSI	41.95
RSI Monthly	40.85
RSI Weekly	38.37
Sharpe ratio	-0.05x
Sortino ratio	0
Total Return	3.69%
Tr YTD	-17.75
Tr15y	105.93%
Tr1m	-7.75%
Tr1w	-1.13%
Tr3m	-13.39%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Ratings	Hold
Earnings EPS Estimate	$2.14
Earnings EPS Estimate Growth	-15.75
Earnings Revenue Estimate	587,375,464x
Earnings Revenue Estimate Growth	0.34x
Operating Income	$276.6M
Operating Income Growth	5.9
Operating Income Growth Q	43.88
Operating Income Growth3 Y	-11.74
Operating Income Growth5 Y	-8.76
Operating margin	10.68
Price target	$333
Price Target Change	$30.31

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	20,902,420%
Float Percent	78.11%
Net Borrowing	-500,000
Shares Insiders	6.55%
Shares Institutions	74.33%
Shares Out	26,761,598
Shares Qo Q	-0.2%
Shares Yo Y	-3.69%
Short Float	0%
Short Ratio	0.16
Short Shares	0

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$299.5M
Average Volume	368.6x
Bv Per Share	255.4
CAPEX	$-153.2M
Ch10y	79.96
Ch15y	105.9
Ch1m	-7.75
Ch1w	-1.13
Ch1y	9.01
Ch20y	261.4
Ch3m	-13.39
Ch3y	-45.39
Ch5y	-59.56
Ch6m	-16.33
Change	-2.19%
Change From Open	0
Close	261.3
Days Gap	-2.19
Depreciation Amortization	168,200,000
Dollar Volume	100,682.8
Earnings Date	2026-04-30
Earnings Time	amc
EBIT	$276.6M
EBITDA	$444.8M
EPS	$6.24
F Score	6
FCF	$357.2M
FCF EV Yield	5.39x
FCF Per Share	$13.35
Financing CF	-229,500,000
Fiscal Year End	December
Founded	1,952
Goodwill	577,100,000
Graham Number	191.35353
Graham Upside	-25.12
Income Tax	$53.5M
Investing CF	-285,800,000
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-04-30
Last Report Date	2026-03-31
Last Split Date	2002-03-08
Last Split Type	Forward
Last10k Filing Date	2026-02-13
Lynch Fair Value	$31.66
Lynch Upside	-87.61
Ma150	441.2
Ma150ch	-42.08%
Ma20	285.3
Ma20ch	-10.42%
Net CF	-14,100,000
Open	255.5
Optionable	No
P FCF Ratio	19.07
P OCF Ratio	13.35
Ppne	689,400,000
Price Date	2026-05-08
Price EBITDA	$15.32
Ptbv Ratio	1.12
Relative Volume	1.07x
Revenue	2,589,900,000x
SBC By Revenue	2.23x
Share Based Comp	57,700,000
Tax By Revenue	2.07x
Tax Rate	24.07%
Tr20y	261.39%
Tr6m	-16.33%
Us State	California
Volume	394
Z Score	3.23

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does BIO.B pay a dividend?

Capital-return profile for this ticker.

Performance

BIO.B stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BIO.B?

Insider, institutional, and short-interest positioning.

Institutional ownership

+74.3%

Float: +78.1% of shares outstanding

Insider ownership

+6.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

BIO.B momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

41.9

Neutral momentum band

Price vs 200-day MA

-47.0%

50/200-day relationship not available

Beta (5Y)

1.16

Moves roughly with the market

Sharpe ratio

-0.05

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BIO.B

Hub-level FAQ points readers to the deeper analysis pages.

What is the current BIO.B stock rating?

Bio-Rad Laboratories, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BIO.B analysis?

The full report lives at /stocks/BIO.B/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for BIO.B?

The latest report frames BIO.B around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the BIO.B page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.